Response to Combined Peptide Receptor Radionuclide Therapy and Checkpoint Immunotherapy with Ipilimumab Plus Nivolumab in Metastatic Merkel Cell Carcinoma.

导出原文传递

翻译打印收藏纠错

第一作者： Justin,Ferdinandus

第一单位： Department of Nuclear Medicine, University of Duisburg-Essen, and German Cancer Consortium, University Hospital Essen, Essen, Germany; justin.ferdinandus@uk-essen.de.

作者： Justin,Ferdinandus ^[1] ; Wolfgang P,Fendler ^[2] ; Katharina,Lueckerath ^[2] ; Christoph,Berliner ^[2] ; Sabine,Kurzidem ^[3] ; Eva,Hadaschik ^[3] ; Joachim,Klode ^[3] ; Lisa,Zimmer ^[3] ; Elisabeth,Livingstone ^[3] ; Dirk,Schadendorf ^[3] ; Ken,Herrmann ^[2] ; Juergen C,Becker ^[4] ; Selma,Ugurel ^[3]

作者单位： Department of Nuclear Medicine, University of Duisburg-Essen, and German Cancer Consortium, University Hospital Essen, Essen, Germany; justin.ferdinandus@uk-essen.de. ^[1] Department of Nuclear Medicine, University of Duisburg-Essen, and German Cancer Consortium, University Hospital Essen, Essen, Germany. ^[2] Department of Dermatology, University of Duisburg-Essen, and German Cancer Consortium, University Hospital Essen, Essen, Germany; and. ^[3] Department of Dermatology, University of Duisburg-Essen, and German Cancer Consortium, University Hospital Essen, Essen, Germany; and.;Translational Skin Cancer Research, University Medicine Essen, Essen, Germany. ^[4]

关键词 Merkel cell carcinoma PD-L1 PRRT SSTR immunotherapy